David Andrew Riseberg MD

Oncology•Baltimore, MD

medical oncologist & hematologist

Join to View Full Profile

227 Saint Paul StBaltimore, MD 21202
Phone+1 410-783-5858
Fax+1 410-783-5864

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1989 - 1992
University of Maryland School of MedicineClass of 1989

Certifications & Licensure

MD State Medical License 1990 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Start of enrollment: 2015 Jul 23
COMPLETED
PHASE3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

12 citations
Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy
Lisa Gallicchio, Carla Calhoun, David A. Riseberg, Kathy J. Helzlsouer
The Breast Journal. 2017-03-01
Response to Dr. Altundag's Letter to the Editor.
Lisa Gallicchio, Carla Calhoun, David A. Riseberg, Kathy J. Helzlsouer
The Breast Journal. 2017-02-01
10 citations
Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer.
David A. Riseberg
Clinical Medicine Insights. Oncology. 2015-08-24

Press Mentions

The Woman's Doctor: Tips on Breast Cancer FatigueJune 27th, 2022
Mercy Medical Oncologists Drs. David Riseberg and Sandy Kotiah to Appear on Mercy’s Ongoing “MEDOSCOPY” SeriesJune 22nd, 2022
HER2-Positive Breast Cancer Patient Being Treated with Newly Approved DrugsSeptember 30th, 2021
Join now to see all